Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis
Purpose To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years. Methods We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis...
Gespeichert in:
| Veröffentlicht in: | Infection 2018-10, Vol.46 (5), p.607-615 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 615 |
|---|---|
| container_issue | 5 |
| container_start_page | 607 |
| container_title | Infection |
| container_volume | 46 |
| creator | Ascione, Antonio De Luca, Massimo Melazzini, Mario Montilla, Simona Trotta, Maria Paola Petta, Salvatore Puoti, Massimo Sangiovanni, Vincenzo Messina, Vincenzo Bruno, Savino Izzi, Antonio Villa, Erica Aghemo, Alessio Zignego, Anna Linda Orlandini, Alessandra Fontanella, Luca Gasbarrini, Antonio Marzioni, Marco Giannini, Edoardo G. Craxì, Antonio |
| description | Purpose
To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years.
Methods
We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12 weeks after the end of treatment (SVR12).
Results
Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A multivariate analysis found albumin |
| doi_str_mv | 10.1007/s15010-018-1157-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2695264158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2045840681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358x-4e64c127741f81a58d963d6f101ea187f8fbccdc325a86c1827f14319cec603e3</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS0EopeWB2CDLLFOOxP_xFmiK6CVKrEAurUcx25d9cbBTsrNK_AUPAtPVke3wKpIluZ4_M0ZyYeQNwinCNCcZRSAUAGqClE01f4Z2SBnbQVtw56TDTCASmEtj8irnG8BQLS8eUmO6laB4pJtyM8vxrtpoWboqfM-WGMXGj2Nuy5MJt-HdDaaVOSY3HopMg5mVb3JppuLouPdnGkK3doOAy1nNFNww5RpvHeJSvH71-JMyvRHmG7o-faKXrshTsvoKFIbUrqJOeQT8sKbu-xeP9Zj8u3jh6_b8-ry86eL7fvLyjKh9hV3klusm4ajV2iE6lvJeukR0BlUjVe-s7a3rBZGSYuqbnz5FGytsxKYY8fk3cF3TPH77PKkb-OchrJS17IVteQo1H8p4EJxkAoLhQfKpphzcl6PKexMWjSCXjPSh4x0yUivGel9mXn76Dx3O9f_nfgTSgHqA5DL03Dt0r_VT7s-AB29nvc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2045840681</pqid></control><display><type>article</type><title>Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Ascione, Antonio ; De Luca, Massimo ; Melazzini, Mario ; Montilla, Simona ; Trotta, Maria Paola ; Petta, Salvatore ; Puoti, Massimo ; Sangiovanni, Vincenzo ; Messina, Vincenzo ; Bruno, Savino ; Izzi, Antonio ; Villa, Erica ; Aghemo, Alessio ; Zignego, Anna Linda ; Orlandini, Alessandra ; Fontanella, Luca ; Gasbarrini, Antonio ; Marzioni, Marco ; Giannini, Edoardo G. ; Craxì, Antonio</creator><creatorcontrib>Ascione, Antonio ; De Luca, Massimo ; Melazzini, Mario ; Montilla, Simona ; Trotta, Maria Paola ; Petta, Salvatore ; Puoti, Massimo ; Sangiovanni, Vincenzo ; Messina, Vincenzo ; Bruno, Savino ; Izzi, Antonio ; Villa, Erica ; Aghemo, Alessio ; Zignego, Anna Linda ; Orlandini, Alessandra ; Fontanella, Luca ; Gasbarrini, Antonio ; Marzioni, Marco ; Giannini, Edoardo G. ; Craxì, Antonio ; ABACUS Study Group ; For the ABACUS Study Group</creatorcontrib><description>Purpose
To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years.
Methods
We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12 weeks after the end of treatment (SVR12).
Results
Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A multivariate analysis found albumin < 3.5 g/dL (OR 2.04: 95% CI 1.0–4.2,
p
< 0.05) and hypertension (OR 4.6: 95% CI 2.3–9.2,
p
< 0.001) as variables independently associated with AE occurrence. The SVR12 was 95% (228/240). Multivariate analysis identified baseline bilirubin < 2 mg/dL (OR 4.9: 95% CI 1.17–20.71,
p
= 0.029) as the only variable independently associated with SVR12.
Conclusion
Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65.</description><identifier>ISSN: 0300-8126</identifier><identifier>EISSN: 1439-0973</identifier><identifier>DOI: 10.1007/s15010-018-1157-x</identifier><identifier>PMID: 29808463</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject><![CDATA[Aged ; Aged, 80 and over ; Albumins ; Anilides - administration & dosage ; Antiretroviral drugs ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Bilirubin ; Biomarkers ; Carbamates - administration & dosage ; Cirrhosis ; Drug therapy ; Drug Therapy, Combination ; Effectiveness ; Family Medicine ; Female ; General Practice ; Genotype ; Genotypes ; Hepacivirus - genetics ; Hepatitis C ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - diagnosis ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; Humans ; Hypertension ; Infectious Diseases ; Interferon ; Internal Medicine ; Liver cirrhosis ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - etiology ; Liver diseases ; Macrocyclic Compounds - administration & dosage ; Male ; Medicine ; Medicine & Public Health ; Multivariate analysis ; Original Paper ; Patient safety ; Patients ; Pharmacokinetics ; Pharmacology ; Ribavirin ; Ribavirin - administration & dosage ; Ribonucleic acid ; Ritonavir ; Ritonavir - administration & dosage ; RNA ; Safety ; Sulfonamides - administration & dosage ; Treatment Outcome ; Uracil - administration & dosage ; Uracil - analogs & derivatives ; Viruses]]></subject><ispartof>Infection, 2018-10, Vol.46 (5), p.607-615</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>Infection is a copyright of Springer, (2018). All Rights Reserved.</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358x-4e64c127741f81a58d963d6f101ea187f8fbccdc325a86c1827f14319cec603e3</citedby><cites>FETCH-LOGICAL-c358x-4e64c127741f81a58d963d6f101ea187f8fbccdc325a86c1827f14319cec603e3</cites><orcidid>0000-0003-2040-8380</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s15010-018-1157-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s15010-018-1157-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29808463$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ascione, Antonio</creatorcontrib><creatorcontrib>De Luca, Massimo</creatorcontrib><creatorcontrib>Melazzini, Mario</creatorcontrib><creatorcontrib>Montilla, Simona</creatorcontrib><creatorcontrib>Trotta, Maria Paola</creatorcontrib><creatorcontrib>Petta, Salvatore</creatorcontrib><creatorcontrib>Puoti, Massimo</creatorcontrib><creatorcontrib>Sangiovanni, Vincenzo</creatorcontrib><creatorcontrib>Messina, Vincenzo</creatorcontrib><creatorcontrib>Bruno, Savino</creatorcontrib><creatorcontrib>Izzi, Antonio</creatorcontrib><creatorcontrib>Villa, Erica</creatorcontrib><creatorcontrib>Aghemo, Alessio</creatorcontrib><creatorcontrib>Zignego, Anna Linda</creatorcontrib><creatorcontrib>Orlandini, Alessandra</creatorcontrib><creatorcontrib>Fontanella, Luca</creatorcontrib><creatorcontrib>Gasbarrini, Antonio</creatorcontrib><creatorcontrib>Marzioni, Marco</creatorcontrib><creatorcontrib>Giannini, Edoardo G.</creatorcontrib><creatorcontrib>Craxì, Antonio</creatorcontrib><creatorcontrib>ABACUS Study Group</creatorcontrib><creatorcontrib>For the ABACUS Study Group</creatorcontrib><title>Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis</title><title>Infection</title><addtitle>Infection</addtitle><addtitle>Infection</addtitle><description>Purpose
To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years.
Methods
We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12 weeks after the end of treatment (SVR12).
Results
Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A multivariate analysis found albumin < 3.5 g/dL (OR 2.04: 95% CI 1.0–4.2,
p
< 0.05) and hypertension (OR 4.6: 95% CI 2.3–9.2,
p
< 0.001) as variables independently associated with AE occurrence. The SVR12 was 95% (228/240). Multivariate analysis identified baseline bilirubin < 2 mg/dL (OR 4.9: 95% CI 1.17–20.71,
p
= 0.029) as the only variable independently associated with SVR12.
Conclusion
Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Albumins</subject><subject>Anilides - administration & dosage</subject><subject>Antiretroviral drugs</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Bilirubin</subject><subject>Biomarkers</subject><subject>Carbamates - administration & dosage</subject><subject>Cirrhosis</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Effectiveness</subject><subject>Family Medicine</subject><subject>Female</subject><subject>General Practice</subject><subject>Genotype</subject><subject>Genotypes</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - diagnosis</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Infectious Diseases</subject><subject>Interferon</subject><subject>Internal Medicine</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver diseases</subject><subject>Macrocyclic Compounds - administration & dosage</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multivariate analysis</subject><subject>Original Paper</subject><subject>Patient safety</subject><subject>Patients</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Ribavirin</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribonucleic acid</subject><subject>Ritonavir</subject><subject>Ritonavir - administration & dosage</subject><subject>RNA</subject><subject>Safety</subject><subject>Sulfonamides - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Uracil - administration & dosage</subject><subject>Uracil - analogs & derivatives</subject><subject>Viruses</subject><issn>0300-8126</issn><issn>1439-0973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc1u1TAQhS0EopeWB2CDLLFOOxP_xFmiK6CVKrEAurUcx25d9cbBTsrNK_AUPAtPVke3wKpIluZ4_M0ZyYeQNwinCNCcZRSAUAGqClE01f4Z2SBnbQVtw56TDTCASmEtj8irnG8BQLS8eUmO6laB4pJtyM8vxrtpoWboqfM-WGMXGj2Nuy5MJt-HdDaaVOSY3HopMg5mVb3JppuLouPdnGkK3doOAy1nNFNww5RpvHeJSvH71-JMyvRHmG7o-faKXrshTsvoKFIbUrqJOeQT8sKbu-xeP9Zj8u3jh6_b8-ry86eL7fvLyjKh9hV3klusm4ajV2iE6lvJeukR0BlUjVe-s7a3rBZGSYuqbnz5FGytsxKYY8fk3cF3TPH77PKkb-OchrJS17IVteQo1H8p4EJxkAoLhQfKpphzcl6PKexMWjSCXjPSh4x0yUivGel9mXn76Dx3O9f_nfgTSgHqA5DL03Dt0r_VT7s-AB29nvc</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Ascione, Antonio</creator><creator>De Luca, Massimo</creator><creator>Melazzini, Mario</creator><creator>Montilla, Simona</creator><creator>Trotta, Maria Paola</creator><creator>Petta, Salvatore</creator><creator>Puoti, Massimo</creator><creator>Sangiovanni, Vincenzo</creator><creator>Messina, Vincenzo</creator><creator>Bruno, Savino</creator><creator>Izzi, Antonio</creator><creator>Villa, Erica</creator><creator>Aghemo, Alessio</creator><creator>Zignego, Anna Linda</creator><creator>Orlandini, Alessandra</creator><creator>Fontanella, Luca</creator><creator>Gasbarrini, Antonio</creator><creator>Marzioni, Marco</creator><creator>Giannini, Edoardo G.</creator><creator>Craxì, Antonio</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0003-2040-8380</orcidid></search><sort><creationdate>20181001</creationdate><title>Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis</title><author>Ascione, Antonio ; De Luca, Massimo ; Melazzini, Mario ; Montilla, Simona ; Trotta, Maria Paola ; Petta, Salvatore ; Puoti, Massimo ; Sangiovanni, Vincenzo ; Messina, Vincenzo ; Bruno, Savino ; Izzi, Antonio ; Villa, Erica ; Aghemo, Alessio ; Zignego, Anna Linda ; Orlandini, Alessandra ; Fontanella, Luca ; Gasbarrini, Antonio ; Marzioni, Marco ; Giannini, Edoardo G. ; Craxì, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358x-4e64c127741f81a58d963d6f101ea187f8fbccdc325a86c1827f14319cec603e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Albumins</topic><topic>Anilides - administration & dosage</topic><topic>Antiretroviral drugs</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Bilirubin</topic><topic>Biomarkers</topic><topic>Carbamates - administration & dosage</topic><topic>Cirrhosis</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Effectiveness</topic><topic>Family Medicine</topic><topic>Female</topic><topic>General Practice</topic><topic>Genotype</topic><topic>Genotypes</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - diagnosis</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Infectious Diseases</topic><topic>Interferon</topic><topic>Internal Medicine</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver diseases</topic><topic>Macrocyclic Compounds - administration & dosage</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multivariate analysis</topic><topic>Original Paper</topic><topic>Patient safety</topic><topic>Patients</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Ribavirin</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribonucleic acid</topic><topic>Ritonavir</topic><topic>Ritonavir - administration & dosage</topic><topic>RNA</topic><topic>Safety</topic><topic>Sulfonamides - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Uracil - administration & dosage</topic><topic>Uracil - analogs & derivatives</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ascione, Antonio</creatorcontrib><creatorcontrib>De Luca, Massimo</creatorcontrib><creatorcontrib>Melazzini, Mario</creatorcontrib><creatorcontrib>Montilla, Simona</creatorcontrib><creatorcontrib>Trotta, Maria Paola</creatorcontrib><creatorcontrib>Petta, Salvatore</creatorcontrib><creatorcontrib>Puoti, Massimo</creatorcontrib><creatorcontrib>Sangiovanni, Vincenzo</creatorcontrib><creatorcontrib>Messina, Vincenzo</creatorcontrib><creatorcontrib>Bruno, Savino</creatorcontrib><creatorcontrib>Izzi, Antonio</creatorcontrib><creatorcontrib>Villa, Erica</creatorcontrib><creatorcontrib>Aghemo, Alessio</creatorcontrib><creatorcontrib>Zignego, Anna Linda</creatorcontrib><creatorcontrib>Orlandini, Alessandra</creatorcontrib><creatorcontrib>Fontanella, Luca</creatorcontrib><creatorcontrib>Gasbarrini, Antonio</creatorcontrib><creatorcontrib>Marzioni, Marco</creatorcontrib><creatorcontrib>Giannini, Edoardo G.</creatorcontrib><creatorcontrib>Craxì, Antonio</creatorcontrib><creatorcontrib>ABACUS Study Group</creatorcontrib><creatorcontrib>For the ABACUS Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><jtitle>Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ascione, Antonio</au><au>De Luca, Massimo</au><au>Melazzini, Mario</au><au>Montilla, Simona</au><au>Trotta, Maria Paola</au><au>Petta, Salvatore</au><au>Puoti, Massimo</au><au>Sangiovanni, Vincenzo</au><au>Messina, Vincenzo</au><au>Bruno, Savino</au><au>Izzi, Antonio</au><au>Villa, Erica</au><au>Aghemo, Alessio</au><au>Zignego, Anna Linda</au><au>Orlandini, Alessandra</au><au>Fontanella, Luca</au><au>Gasbarrini, Antonio</au><au>Marzioni, Marco</au><au>Giannini, Edoardo G.</au><au>Craxì, Antonio</au><aucorp>ABACUS Study Group</aucorp><aucorp>For the ABACUS Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis</atitle><jtitle>Infection</jtitle><stitle>Infection</stitle><addtitle>Infection</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>46</volume><issue>5</issue><spage>607</spage><epage>615</epage><pages>607-615</pages><issn>0300-8126</issn><eissn>1439-0973</eissn><abstract>Purpose
To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years.
Methods
We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12 weeks after the end of treatment (SVR12).
Results
Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A multivariate analysis found albumin < 3.5 g/dL (OR 2.04: 95% CI 1.0–4.2,
p
< 0.05) and hypertension (OR 4.6: 95% CI 2.3–9.2,
p
< 0.001) as variables independently associated with AE occurrence. The SVR12 was 95% (228/240). Multivariate analysis identified baseline bilirubin < 2 mg/dL (OR 4.9: 95% CI 1.17–20.71,
p
= 0.029) as the only variable independently associated with SVR12.
Conclusion
Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>29808463</pmid><doi>10.1007/s15010-018-1157-x</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2040-8380</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8126 |
| ispartof | Infection, 2018-10, Vol.46 (5), p.607-615 |
| issn | 0300-8126 1439-0973 |
| language | eng |
| recordid | cdi_proquest_journals_2695264158 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Aged, 80 and over Albumins Anilides - administration & dosage Antiretroviral drugs Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Bilirubin Biomarkers Carbamates - administration & dosage Cirrhosis Drug therapy Drug Therapy, Combination Effectiveness Family Medicine Female General Practice Genotype Genotypes Hepacivirus - genetics Hepatitis C Hepatitis C, Chronic - complications Hepatitis C, Chronic - diagnosis Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans Hypertension Infectious Diseases Interferon Internal Medicine Liver cirrhosis Liver Cirrhosis - diagnosis Liver Cirrhosis - etiology Liver diseases Macrocyclic Compounds - administration & dosage Male Medicine Medicine & Public Health Multivariate analysis Original Paper Patient safety Patients Pharmacokinetics Pharmacology Ribavirin Ribavirin - administration & dosage Ribonucleic acid Ritonavir Ritonavir - administration & dosage RNA Safety Sulfonamides - administration & dosage Treatment Outcome Uracil - administration & dosage Uracil - analogs & derivatives Viruses |
| title | Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T11%3A03%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20ombitasvir/paritaprevir/ritonavir/dasabuvir%20plus%20ribavirin%20in%20patients%20over%2065%C2%A0years%20with%20HCV%20genotype%201%20cirrhosis&rft.jtitle=Infection&rft.au=Ascione,%20Antonio&rft.aucorp=ABACUS%20Study%20Group&rft.date=2018-10-01&rft.volume=46&rft.issue=5&rft.spage=607&rft.epage=615&rft.pages=607-615&rft.issn=0300-8126&rft.eissn=1439-0973&rft_id=info:doi/10.1007/s15010-018-1157-x&rft_dat=%3Cproquest_cross%3E2045840681%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2045840681&rft_id=info:pmid/29808463&rfr_iscdi=true |